Supporting the potential importance of this observation, activity of the first-generation BCL-2 antagonists has indicated that BCL-2 inhibition could be exploited for MLLr leukemias (Robinson et al., 2008, Urtishak et al., 2013). This evidence concerns the gene BCL2 and leukemia.